logo
Plus   Neg
Share
Email

Roche Collects Data On Actemra' Potential Utility In COVID-19 Pneumonia Patients

Roche said that it has initiated global phase III study and collected data on Actemra's potential utility in severe COVID-19 pneumonia patients.

The study, COVACTA, will evaluate the safety and efficacy of intravenous Actemra/RoActemra on top of standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo on top of standard of care.

At present, there are no studies showing safety and efficacy of Actemra in clinical treatment of COVID-19 pneumonia, and Actemra is not currently approved for this use.

Roche said it is working urgently to accelerate manufacturing capacity to maximize production of Actemra wherever possible with the goal of increasing available supply globally.

On March 12, Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 Test to detect the novel virus that causes COVID-19 disease. The test is also available in markets accepting the CE mark.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Netflix Inc. (NFLX) - Shares of the video streaming giant jumped 12% after it reported fourth-quarter results and strong subscriber additions. Netflix added 8.51 million subscribers globally in the quarter, far ahead of its forecast of 6.00 million, to end the quarter with 203.66 million subscribers.... Best Buy said it is partnering Popsockets to bring products designed by teens from the company's community programs to its store shelves. The electronics retailer will sell the teen-designed PopGrips in its stores as part of its "Black History Month" campaign. The campaign is intended to celebrate and encourage young artists. Goldman Sachs Group Inc. (GS) on Tuesday reported a fourth-quarter profit that more than doubled from last year, reflecting a surge in investment banking revenues and lower provisions for bad loans. Net revenues for the quarter rose 18 percent. Both quarterly earnings per share and revenues topped analysts' expectations.
Follow RTT